RxDoctor Payments Data

Maria de Leon, MD

Family Medicine · Orlando, FLNPI 1578573093

Payments from drug & device makers

$998in general payments, 2019–2025

Across 27 payments — averaging $36.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$143
  • Pfizer$139
  • Novo Nordisk$129
  • AbbVie$123
  • Phathom Pharmaceuticals, Inc.$118
  • GSK$92
  • plus $254 from 7 others

What the payments were for

  • Food & beverage$98098%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$998 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$76,462
Medicare patients
222
Services billed
849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$75,689
EliquisApixaban30$50,739
OzempicSemaglutide23$28,690
Tresiba Flextouch U-100Insulin Degludec21$20,000
JanuviaSitagliptin Phosphate12$12,233
TradjentaLinagliptin12$8,285
Atorvastatin Calcium622$4,245
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,027
Levothyroxine Sodium323$3,430
PremarinEstrogens, Conjugated11$2,789
SynthroidLevothyroxine Sodium26$2,538
Rosuvastatin Calcium278$2,414
Gabapentin135$2,248
Losartan Potassium280$2,221
Nano 2nd Gen Pen NeedlePen Needle, Diabetic19$1,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$139$53,52841 claims
Novo NordiskOzempic$129$28,69023 claims
MerckJanuvia$24$12,23312 claims
AbbVieSynthroid$123$2,53826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →